-
Oct 30, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
European Commission Imposes Heavy Fine on Teva for Misuse of Patent System and Disparaging Rival’s Product*Today, the European Commission (the Commission) fined Teva EUR 462.6 million for abusing its dominant position to delay the market entry of rival medicines for the treatment of relapsing forms of multiple sclerosis (see, attached press release and statement). The Commission established that Teva artificially delayed competition and extended the patent protection of its product Copaxone®...
-
Oct 30, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
European Commission Imposes Heavy Fine on Teva for Misuse of Patent System and Disparaging Rival’s Product*Today, the European Commission (the Commission) fined Teva EUR 462.6 million for abusing its dominant position to delay the market entry of rival medicines for the treatment of relapsing forms of multiple sclerosis (see, attached press release and statement). The Commission established that Teva artificially delayed competition and extended the patent protection of its product Copaxone®...
-
Oct 9, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
Previous article Next article Share on | The Swiss Competition Authority ( Competition Commission or Comco ) indicated today that it terminated its inquiry into patent litigation conducted by Novartis to protect Cosentyx®, a human IgG1 monoclonal antibody indicated for the treatment of several autoimmune diseases, including specific dermatological conditions (see, attached press release in four language versions). Both Comco and the European Commission (the Commission ) had sought to learn...
-
Sep 2, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Valérie Lefever
Previous article Next article Share on | Yesterday, the Grand Chamber of the Court of Justice of the European Union (the CJEU ) set aside the judgment in which the General Court ( GC ) had confirmed the competence of the European Commission (the Commission ) to review (and ultimately prohibit) the acquisition of Grail by Illumina and annulled the Commission’s decisions to accept to review this case following referral requests by France and other Member States (CJEU, judgment of 3 September in...
-
Sep 2, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Valérie Lefever
Yesterday, the Grand Chamber of the Court of Justice of the European Union (the CJEU ) set aside the judgment in which the General Court ( GC ) had confirmed the competence of the European Commission (the Commission ) to review (and ultimately prohibit) the acquisition of Grail by Illumina and annulled the Commission’s decisions to accept to review this case following referral requests by France and other Member States (CJEU, judgment of 3 September in Joined Cases C-611/22 P and C-625/22 P...
-
Aug 28, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
-
Aug 28, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
-
Aug 28, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
-
Jul 28, 2024 | 
concurrences.com | Van Bael |Trajan Shipley |Giovanni Pregno |Michael Clancy
On 29 July 2024, the Spanish Competition Authority (“SCA”) imposed its largest ever fine (€ 413 million) on Booking.com, the leading online travel agent, for abusing its dominant position in the market for intermediary online travel agent services for hotels. In its decision, the SCA found that Booking.com committed an exploitative abuse by imposing unfair trading conditions on hotels. According to the applicable case-law (see BRT v SABAM, C-127/73), unfair trading conditions imposed by a dom...
-
Jul 25, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
Previous article Next article Share on | On 26 July 2024, the European Commission (the Commission ) authorised a EUR 2 billion financing scheme by the Dutch government to support the construction and operation of a nuclear reactor and health centre in Petten, the Netherlands (see, attached Commission press release). The nuclear reactor, called Pallas, will produce medical isotopes as the successor of the existing High Flux Reactor ( HFR ) which has been one of the global leaders for the...
